A New Vision for Precision Medicine

Our team is dedicated to pioneering precision medicine in inflammatory disease by harnessing the power of single-cell RNA sequencing and human disease biology at scale.

Mission & Vision

Celsius is a New Way of Seeing

We’ve taken a new approach to understand human disease biology through a powerful combination of single-cell genomics and machine learning.

Celsius is Developing Precision Therapies for Complex, Multifactorial Diseases

The promise of precision medicine has yet to benefit immuno-inflammatory diseases. Now, with new insights, we can build a broad therapeutics pipeline, identify targeted patient populations and design smarter clinical studies in these complex conditions.

Collaboration is at the Core of all We Do

Collaboration is a fundamental tenet of our ecosystem. Our multidisciplinary team incorporates various perspectives to drive towards new therapies, while our external partnerships expand the reach of what’s possible.


The Art of Seeing What is Invisible to Others

Celsius is poised to establish a new era of precision therapies for inflammatory diseases.

Observation. Insights. Action. 

Translating complex biological information into impactful therapies for patients requires relentless determination, the ability to connect diverse data points and immeasurable curiosity. 

We believe we are at the cusp of another transformational era of medicine with the advent of new technologies that allow us to see and understand cells in completely new ways, most notably single-cell RNA sequencing and machine learning. What sets Celsius apart is how we apply the power of these technologies at scale to observe cellular programs in actual human disease.

Our SCOPE platform enables us to identify new targets and patient subsets in complex, multifactorial diseases. The ability to “see” the behavior of human cells in disease progression means that we can design more targeted discovery and development programs and build an extensive pipeline of drugs.

Board of Directors

Neil Exter

Neil Exter

Partner, Third Rock Ventures

Suzanne Jung Angell

Suzanne Jung Angell

Director of Therapeutic Research, Casdin Capital

Tariq Kassum, M.D.

Tariq Kassum, M.D.

Chief Executive Officer

Christoph Lengauer, Ph.D.

Christoph Lengauer, Ph.D.

Co-Founder, Curie.Bio

René Russo, Pharm.D.

René Russo, Pharm.D.

CEO, Xilio Therapeutics

Andrea van Elsas, Ph.D.

Andrea van Elsas, Ph.D.

Venture Partner, Third Rock Ventures


Jeffrey Bluestone, Ph.D.

President and CEO, Sonoma Biotherapeutics

Vijay Kuchroo, DVM, Ph.D.

Samuel L. Wasserstrom Professor of Neurology, Harvard Medical School

Christoph Lengauer, Ph.D.

Co-Founder, Curie.Bio

Aviv Regev, Ph.D.

Head of Genentech Research & Early Development (gRED)

Ramnik Xavier, M.D., Ph.D.

Core Institute Member, Broad Institute, and Kurt Isselbacher Professor of Medicine, Harvard Medical School

Scientific Advisory Board

Maria T. Abreu, M.D.

Director, Crohn’s and Colitis Center, Professor of Medicine, and Professor of Microbiology and Immunology, University of Miami, Miller School of Medicine

Richard Flavell, Ph.D., FRS

Sterling Professor of Immunobiology, Yale University School of Medicine

Peter Kharchenko, Ph.D.

Principal Scientist, Altos Labs San Diego Institute; Gilbert S. Omenn Associate Professor of Biomedical Informatics, Harvard Medical School

Florian Rieder, M.D.

Vice Chair, Co-Director IBD Section, Director IBD Research, Director IBD Advanced Fellowship, Cleveland Clinic

Ton N. Schumacher, Ph.D.

Senior Member, The Netherlands Cancer Institute

Nir Yosef, Ph.D.

Associate Professor, Department of Systems Immunology, Weizmann Institute; Associate Professor, Department of Electrical Engineering and Computer Science, UC Berkeley 

Our Investors